WLWanli Lin

Wanli Lin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wanli Lin has a total of 117 co-authors. Here are the top co-authors by number of shared publications:

  • Yujie Xie

    Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China

    6 shared publications
  • Bomeng Wu

    Department of Thoracic Surgery, Affiliated Gaozhou People’s Hospital, Guangdong Medical University

    5 shared publications
  • Hai Zhang

    Department of Thoracic Surgery, Affiliated Gaozhou People’s Hospital, Guangdong Medical University

    5 shared publications
  • Haiquan He

    Department of Thoracic Surgery, Gaozhou People's Hospital, Guangdong Esophageal Cancer Institute Gaozhou, Gaozhou, China

    4 shared publications
  • Jiangbo Lin

    Department of Thoracic Surgery, Fujian Medical University Union Hospital

    4 shared publications
  • Cui Li

    Department of Thoracic Surgery, Gaozhou People’s Hospital, Guangdong Esophageal Cancer Institute Gaozhou, Gaozhou, China

    3 shared publications

Latest Publications

  • Open Access

    Efficacy comparison of neoadjuvant chemotherapy, chemoradiotherapy, and chemoimmunotherapy in resectable esophageal squamous cell carcinoma: short- and long-term outcomes from a propensity score-matched analysis

    by Hai Zhang, Yujing Liang, Chaolin Li, Bomeng Wu, Jiangbo Lin, Wanli Lin

    Introduction: This study consecutively enrolled patients with resectable locally advanced esophageal squamous cell carcinoma (ESCC) treated at Fujian Medical University Union Hospital and Gaozhou People's Hospital between January 1, 2,019, and January 1, 2022. Methods: All patients received neoadjuvant therapy followed by minimally invasive McKeown esophagectomy and were categorized according to treatment modality: neoadjuvant chemotherapy (nCT), chemoradiotherapy (nCRT), or chemoimmunotherapy (nICT). Propensity score matching yielded 78 patients per group. The primary endpoints were 3-year overall survival (OS), recurrence-free survival (RFS), and recurrence patterns. Results: One-year RFS was significantly lower in the nCT group than in the nCRT and nICT groups ( p = 0.020), whereas 2-year OS was significantly higher in the nICT group ( p = 0.018). However, no statistically significant differences were observed in 3-year OS or RFS. Recurrence occurred significantly earlier in the nCT group than in the nICT group ( p < 0.05), with no statistically significant differences in the other pairwise comparisons. Discussion: In this retrospective matched-cohort study, nICT did not significantly improve 3-year OS or RFS compared with nCRT, although recurrence appeared to occur later in the nICT group. These findings should be interpreted as hypothesis-generating, as potential long-term immunotherapy effects and radiotherapy-related modulation of long-term benefit could not be assessed. The lower survival observed in the nCT group suggests that chemotherapy alone may be insufficient for ESCC. Prospective trials are warranted to confirm long-term benefits and identify patients most likely to benefit from nICT.

  • Open Access

    Case Report: A seventy-year-stable chest wall bronchogenic cyst with sudden enlargement: coincidence or connection with a concurrent thymic carcinoma?

    by Jiawei Huang, Kairen Xie, Huajun Li, Jing Xie, Yunjie Liang, Ying Chen, Wanli Lin

    Introduction: Bronchogenic cysts arising in the chest wall are uncommon. This report describes a unique case of a chest wall bronchogenic cyst that exhibited delayed proliferation after seventy years of stability, concurrently presenting with a separate anterior mediastinal thymic carcinoma. Case presentation: A 75-year-old woman presented with a six-month history of gradual enlargement of a long-standing, previously stable suprasternal mass. Computed tomography revealed a well-circumscribed subcutaneous cyst and a separate anterior mediastinal mass. Both lesions were completely excised. Histopathology confirmed the chest wall lesion as a bronchogenic cyst and the mediastinal mass as a poorly differentiated squamous cell carcinoma of thymic origin (Masaoka-Koga stage I). The patient recovered well with no recurrence at follow-up. Discussion: While sudden enlargement of bronchogenic cysts is documented, delayed growth after an exceptionally prolonged quiescent period is exceedingly rare. The concurrent discovery of a histologically distinct yet anatomically adjacent thymic carcinoma raises the question of a potential pathological interaction beyond coincidence. Common mechanisms for cyst enlargement, such as infection, haemorrhage, or secretory obstruction, were absent. We hypothesise that paracrine stimulation by factors secreted from the thymic carcinoma may have disrupted the cyst’s homeostasis, prompting its secondary growth. This hypothesis warrants further investigation through molecular analysis of similar cases. Conclusion: We report an exceptionally rare instance of delayed growth in a thoracic wall bronchogenic cyst, occurring after more than seven decades of quiescence and coincident with an anatomically adjacent thymic squamous cell carcinoma. This finding underscores the necessity for comprehensive evaluation of long-standing masses that undergo change; it also provides significant clinical insights, documents a unique case, and suggests avenues for investigating the underlying mechanism.

  • Open Access

    DNASE1L3 functions as a significant metastatic suppressor by attenuating MYH9/β-catenin/c-Jun/LncRNA-KDM4A-induced E-cadherin ubiquitination degradation in nasopharyngeal carcinoma

    by Xingyu Tao, Xiong Liu, Xiangdong Zhao, Beixian Zhou, Chao Cheng, Weiwei Yan, Jingjing He, Haolin Cao, Yun Su, Jianyang Xin, et al.

    Deoxyribonuclease 1 Like 3 (DNASE1L3) is a member of the deoxyribonuclease I family that is associated with some diseases, including systemic lupus erythematosus and hypocomplementemic urticarial vasculitis. Recently, abnormal DNASE1L3 was preliminarily shown to correlate with tumor pathogenesis. However, its role is still undetermined in nasopharyngeal carcinoma (NPC). Multiple sets of Gene Expression Omnibus (GEO) high-throughput data were utilized to screen the differentially expressed genes. Signal pathway enrichment analysis analyzed the correlation between DNASE1L3 and epithelial-mesenchymal transition (EMT) and cytoskeleton reorganization. An immunohistochemistry assay for analysis of DNASE1L3 expression was used to detect the clinical samples. Woundhealing, migration, invasion assays, and mouse model of lung metastasis were used to assess the role of DNASE1L3 in NPC metastasis. The mechanism of DNASE1L3 inhibition of NPC metastasis by attenuating MYH9/β-catenin/c-Jun/LncRNA-KDM4A-induced E-cadherin ubiquitination degradation was demonstrated by protein stability evaluation, co-immunoprecipitation, immunofluorescence, chromatin immunoprecipitation, dual-luciferase reporter assay, and RNA immunoprecipitation. DNASE1L3 downregulation in patients with NPC was not only negatively related to lymph node metastasis and distant metastasis but was also positively associated with poor prognosis. Overexpression of DNASE1L3 in NPC cells suppresses migration, invasion, and metastasis in vitro and in vivo. Inversely, DNASE1L3 knockdown increased cell migration and invasion abilities. Mechanistically, DNASE1L3 recruited PARK2 to ubiquitinate and degrade MYH9 protein. MYH9 protein activated β-catenin/c-Jun signal and augmented c-Jun-induced LncRNA-KDM4A transcription. In the process of DNASE1L3-induced metastatic suppression, decreased LncRNA-KDM4A attenuated the recruitment of E3 ubiquitin ligase Hakai and thus impeded the degradation of E-cadherin, by which heightened E-cadherin protein stability and finally inactivated the EMT signal. Our data firstly elucidated that DNASE1L3 acts as a metastatic suppressor by attenuating E-cadherin ubiquitination degradation via the MYH9/β-catenin/c-Jun/LncRNA-KDM4A axis in NPC. DNASE1L3 is a potential marker for predicting NPC prognosis.

  • Open Access

    Comparison of short-term outcomes of combined neoadjuvant chemotherapy and immunotherapy, neoadjuvant radiotherapy, and neoadjuvant chemotherapy for resectable locally advanced esophageal squamous cell carcinoma

    by Hai Zhang, Zicheng Dai, Bei Wang, Bomeng Wu, Jiangbo Lin, Wanli Lin

    Background: This study aimed to evaluate the safety and efficacy of neoadjuvant immunochemotherapy (nICT) compared to those of neoadjuvant chemoradiotherapy (nCRT) and neoadjuvant chemotherapy (nCT) in patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC). Methods: Patients with locally advanced resectable ESCC undergoing neoadjuvant therapy followed by minimally invasive McKeown esophagectomy (MIE) between January 1, 2019, and January 1, 2022, were categorized into the nCT, nCRT, and nICT groups. Inverse probability of treatment weighting (IPTW) was used to balance the 13 baseline covariates across the groups. Post-IPTW comparisons included adverse events, surgical outcomes, pathologic complete response (PCR), tumor downstaging, and perioperative complications. Results: A total of 437 patients were enrolled (nICT = 218, nCRT = 78, nCT = 141). After propensity score matching (PSM), 78 patients were included in each group. During neoadjuvant therapy, the incidence of leukopenia was significantly higher in the nCRT (33.33%) and nICT (23.08%) groups than in the nCT (10.26%), p < 0.05. Neutropenia rates followed a similar trend (nCRT: 19.23%; nICT: 17.95%; nCT: 2.56%, p < 0.05). Immune-related dermatitis occurred in 10.26% of patients with nICT. Operative duration was significantly longer with nCRT (347.8 ± 80.8 min) than nCT (325.1 ± 52.6 min; p < 0.05). The tumor-downstaging efficacy was ranked as follows: nICT > nCRT > nCT ( p < 0.05). Lymph node dissection:Yields: nCRT (26 ± 11) < nICT (36 ± 14) and nCT (35 ± 12) ( p < 0.05),Stations: nICT (13 ± 4) > nCRT (9 ± 2) and nCT (11 ± 2) ( p < 0.05). The PCR rates were 34.61% (nCRT), 26.92% (nICT), and 5.13% (nCT), respectively ( p < 0.05). Postoperative 30-day mortality occurred in three nCRT and one nCT patients. Postoperative arrhythmia incidence was highest with nICT (12.82%), intermediate with nCT (5.13%), and absent with nCRT (0.00%). Conclusion: For locally advanced resectable ESCC, nCRT requires vigilant management because of its association with grade 3 treatment-related adverse events (AEs). While nICT demonstrates a lower incidence of severe (grade ≥ 3) non-immune toxicities compared to nCRT, supporting its controllable safety. nCRT achieved superior PCR rates versus nICT/nCT, but nICT showed greater nodal (N) downstaging efficacy. Conversely, nCRT provided enhanced primary tumor (T) control.


  • Open Access

    PTGDS deficiency as a driver of M2 macrophage polarization and immunosuppressive microenvironment in esophageal squamous cell carcinoma: an experimental study

    by Jian Zhong, Yujie Xie, Zhengang Zhao, Xianwen Chen, Jianhua Fu, Wanli Lin

    Introduction: Esophageal squamous cell carcinoma (ESCC) exhibits poor survival linked to M2 macrophage-polarized microenvironment. This study aimed to elucidate the role of prostaglandin D2 synthase (PTGDS) in modulating tumor microenvironment (TME) and its prognostic implications in ESCC. Materials and methods: Transcriptomic datasets (GSE53624, GSE121931) were analyzed using immune deconvolution and weighted gene co-expression network analysis to identify genes associated with M2 macrophage infiltration. Differentially expressed genes between tumor and normal tissues were assessed in Gaozhou-RNA cohort. Cox regression analyses were conducted to evaluate prognostic factors. A nomogram incorporating PTGDS expression and clinicopathological parameters was developed and validated by immunohistochemistry (IHC) which was performed in the Gaozhou-IHC cohort. In vitro experiments were used to validate the role of PTGDS. Results: PTGDS expression was significantly downregulated in ESCC tissues and reduced PTGDS expression was identified as a significantly prognostic factor for worse overall survival (OS). A combined nomogram demonstrated strong predictive accuracy, with area under the curve (AUC) values of 0.63, 0.77, and 0.83 for 1-, 3-, and 5-year OS predictions in the GSE53624 cohort, which remained consistent across validation cohorts (GSE121931 and Gaozhou-IHC cohort). Lower PTGDS expression was significantly associated with increased myeloid-derived suppressor cells recruitment, reduced T cell infiltration, and impaired T cell cytotoxicity. IHC confirmed elevated CD206 + M2 macrophage infiltration in PTGDS-low tumors. In vivo and in vitro experiments further demonstrated PTGDS overexpression effectively suppressed M2 macrophage polarization. Conclusion: PTGDS deficiency promotes immunosuppressive TME remodeling and predicts unfavorable clinical outcomes in ESCC, which might be a potential prognostic biomarker in ESCC.


  • Open Access

    Transcriptome analysis and artificial intelligence for predicting lymph node metastasis of esophageal squamous cell carcinoma

    by Zhengang Zhao, Yujie Xie, Dongmei Lai, Jin Liang, Ikenna C. Okereke, Wanli Lin

    Background: Lymph node metastasis (LNM) is the most common route of metastasis in esophageal squamous cell carcinoma (ESCC), and the treatment of patients with ESCC largely depends on the LNM status. The methods for diagnosing LNM in ESCC are still not accurate enough, and accurate LNM staging is crucial for clinical practice. The purpose of this study was to investigate the value of combining transcriptome analysis with artificial intelligence (AI) in predicting LNM and to construct an effective predictive model for LNM in ESCC. Methods: We first enrolled 36 patients with ESCC for RNA sequencing (RNA-seq) to identify the differentially expressed messenger RNA (mRNAs), and then selected candidate genes via a random forest machine learning algorithm. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect the expression of three candidate genes. For the assessment of the overall survival (OS) of patients with ESCC, we used the Kaplan-Meier method and the log-rank test. Univariate and multivariate logistic regression analyses were performed to screen for risk model factors. The model was validated with the area under the curve (AUC) and visualized through a nomogram. For AI model building, random forest was conducted. We included five variables to create the AI model, and divided the data from 209 patients into a training set and a validation set to evaluate the model’s performance. Thereafter, receiver operating characteristic (ROC) curves and the AUC were used to validate the AI system and to conduct subgroup analyses. Results: RNA-seq identified 2,837 genes that were differentially expressed in ESCC tissues with LNM. We used a random forest machine learning algorithm to eliminate candidate diagnostic genes for patients with ESCC with LNM, with the three most diagnostic genes being SIM2, CUX1, and CYP4B1. Analysis of OS indicated that patients with LNM had a worse prognosis. Low expression levels of SIM2 were negatively correlated with OS. However, high expression levels of CUX1 or CYP4B1 were negatively correlated with OS. We added five independent influencing factors to the risk model via univariate and multivariate logistic regression analyses. In the ROC curve analysis, the AUC for the most effective logistic regression model was 0.83. A nomogram was used to display the predictive variables. Finally, these five variables were used to create the AI model, and the AUC was 0.78. Moreover, the subgroup analysis indicated that the AI model that incorporated only the T3 clinical tumor stage yielded an AUC of 0.78. Conclusions: AI and transcriptome analysis can be used to create a risk model for predicting LNM, and it can enhance prediction accuracy and inform clinical staging and decision-making before surgery.


  • Open Access

    IL-19 as a promising theranostic target to reprogram the glioblastoma immunosuppressive microenvironment

    by Gilbert Aaron Lee, Justin Bo-Kai Hsu, Yu-Wei Chang, Li-Chun Hsieh, Yi-Tien Li, Ying Chieh Wu, Cheng-Ying Chu, Yung-Hsiao Chiang, Wan-Yuo Guo, Chih-Chun Wu, et al.

    Background: Glioblastoma multiforme (GBM) is an aggressive brain tumor with chemoresistant, immunosuppressive, and invasive properties. Despite standard therapies, including surgery, radiotherapy, and temozolomide (TMZ) chemotherapy, tumors inevitably recur in the peritumoral region. Targeting GBM-mediated immunosuppressive and invasive properties is a promising strategy to improve clinical outcomes. Methods: We utilized clinical and genomic data from the Taiwan GBM cohort and The Cancer Genome Atlas (TCGA) to analyze RNA sequencing data from patient tumor samples, determining the association of interleukin-19 (Il-19) expression with survival and immunosuppressive activity. Gene set enrichment analysis (GSEA) was performed to assess the relationship between the enrichment levels of immune subsets and Il-19 expression level, and Ingenuity Pathway Analysis (IPA) was used to predict immune responses. Cytokine array and single-cell RNA sequencing were used to examine the effects of IL-19 blockade on tumor immune microenvironment, including tumor-infiltrating leukocyte profiles, differentiation and immunosuppressive genes expression in tumor associated macrophages (TAM). CRISPR Il-19 −/− cell lines and Il-19 −/− mice were used to examine the role of IL-19 in tumor invasion and M2-like macrophage-mediated immunosuppression. Additionally, we developed novel cholesterol-polyethylene glycol-superparamagnetic iron oxide-IL-19 antibody nanoparticles (CHOL-PEG-SPIO-IL-19), characterized them using dynamic light scattering and transmission electron microscopy, Fourier-Transform Infrared spectroscopy, prussian blue assay, and conducted in vivo magnetic resonance imaging (MRI) in a human glioblastoma stem cell-derived GBM animal model. Result: Genomic screening and IPA analysis identified IL-19 as a predicted immunosuppressive cytokine in the peritumoral region, associated with poor survival in patients with GBM. Blocking IL-19 significantly inhibited tumor progression of both TMZ-sensitive (TMZ-S) and TMZ-resistant (TMZ-R) GBM-bearing mice, and modulated the immune response within the GBM microenvironment. Single-cell transcriptome analysis reveal that IL-19 antibody treatment led to a marked increase in dendritic cells and monocyte/macrophage subsets associated with interferon-gamma signaling pathways. IL-19 blockade promoted T cell activation and reprogrammed tumor-associated macrophages toward weakened pro-tumoral phenotypes with reduced Arginase 1 expression. Il19 −/− M2-like bone marrow-derived macrophages with lower Arginase 1 level lost their ability to suppress CD8 T cell activation. These findings indicated that IL-19 suppression limits TAM-mediated immune suppression. Molecular studies revealed that IL-19 promotes TMZ-resistant GBM cell migration and invasion through a novel IL-19/WISP1 signaling pathway. For clinical translation, we developed a novel CHOL-PEG-SPIO-IL-19 nanoparticles to target IL-19 expression in glioblastoma tissue. MRI imaging demonstrated enhanced targeting efficiency in brain tumors, with in vivo studies showing prominent hypointense areas in T2*-weighted MRI scans of tumor-bearing mice injected with CHOL-PEG-SPIO-IL-19, highlighting nanoparticle presence in IL-19-expressing regions. Prussian blue staining further confirmed the localization of these nanoparticles in tumor tissues, verifying their potential as a diagnostic tool for detecting IL-19 expression in glioblastoma. This system offers a theranostic approach, integrating diagnostic imaging and targeted therapy for IL-19-expressing GBM. Conclusion: IL-19 is a promising theranostic target for reversing immunosuppression and restricting the invasive activity of chemoresistant GBM cells. Graphical


  • Open Access

    Higher 3-year recurrence-free survival rate in patients with complete pathological remission following neoadjuvant chemotherapy plus immunotherapy for esophageal cancer: a two-center, propensity score matching study

    by Hai Zhang, Haiquan He, Qingyi Feng, Bomeng Wu, Ying Chen, Zhenyang Zhang, Linrong Zhou, Cui Li, Wanli Lin, Jiangbo Lin

    Background: Neoadjuvant therapy is preferentially recommended for resectable locally advanced esophageal malignancies, with patients who achieve pathological complete response (PCR) anticipated to have longer survival rates. The aim of this study was to compare 3-year follow-up data for patients with esophageal malignancy who achieved PCR through neoadjuvant chemotherapy (nCRT) and to compare the findings with those of neoadjuvant immunotherapy plus chemotherapy (nICT).Methods: This retrospective study included 85 patients with esophageal cancer who underwent surgical resection following nCRT (n=47) or nICT (n=38) between January 1, 2016 and January 1, 2020 at Fujian Medical University Union Hospital and Gaozhou People’s Hospital. Propensity score matching was used to match baseline data and reduce bias between the patient groups. Data during the neoadjuvant treatment and perioperative periods were compared, and follow-up was performed to evaluate differences in 3-year survival rate and recurrence-free survival.Results: After propensity score matching, 28 nCRT patients and 38 nICT patients were included. During neoadjuvant therapy, the nCRT group had higher incidences of leukopenia and neutropenia than did the nICT group. No significant differences were observed in the incidences of hemoglobin decrease, platelet decrease, liver function damage, elevated serum creatinine, diarrhea, radioactive pneumonia or immunotherapy-related pneumonia, and esophageal perforation. The nCRT group had fewer lymph node dissections and lymph node stations. Postoperative lung infection (50.00%) was significantly higher in the nICT group than in the nCRT group (25.00%). The 3-year survival rates were 97.37% and 85.71% in the nICT and nCRT groups, respectively; the 3-year recurrence-free survival rate was significantly lower in the nCRT group (82.14%) than in the nICT group (97.37%, P=0.02).Conclusions: These findings suggest that patients with esophageal cancer who achieve PCR after nICT treatment may have lower rates of disease recurrence.

  • Open Access

    Identification and validation of LINC02381 as a biomarker associated with lymph node metastasis in esophageal squamous cell carcinoma

    by Jin Liang, Zhengang Zhao, Yujie Xie, Dongmei Lai, Ikenna C. Okereke, Jeffrey B. Velotta, Emmanuel Gabriel, Wanli Lin

    Background: The treatment of esophageal squamous cell carcinoma (ESCC) patients varies considerably depending upon whether lymph node metastasis (LNM) is present. Patients with ESCC can particularly benefit from neoadjuvant therapy if LNM is accurately diagnosed before surgery. Long noncoding RNA (lncRNA) has been confirmed to be closely related to the development of metastases in ESCC, but much remains unknown regarding the relationship between LNM and lncRNA. The purpose of our study was to investigate relationship between LNM and lncRNA, and create a diagnostic model for predicting LNM in ESCC before surgery. Methods: We used quantitative real-time polymerase chain reaction (qRT-PCR) to detect the expression of LINC02381. We also verified the in vitro effect of LINC02381 on the growth and metastasis of ESCC in the KYSE510 and KYSE180 cell lines. We used the Kaplan-Meier (KM) method and the log-rank test to confirm the differences of overall survival (OS) and disease-free survival (DFS) in LINC02381 expression. We used univariate and multivariate logistic regression analyses to screen for clinical characteristics and assessed their clinical diagnostic efficacy using receiver operating characteristic (ROC) curves. The model was validated with the area under the curve (AUC) and calibration curves and visualized through a nomogram. Results: qRT-PCR suggested a significant elevation of LINC02381 expression in ESCC tissues compared with normal esophageal epithelial tissues (PConclusions: LINC02381 may serve as a biomarker for predicting LNM. Our risk model can assist in predicting LNM in clinical practice, inform the decision to implement neoadjuvant therapy before surgery, and therefore improve prognosis.


  • Open Access

    Minimally invasive esophagectomy with non-invasive ventilation by laryngeal mask-assisted anesthesia for esophageal squamous cell carcinoma: case report

    by Weibi Che, Jian Zhong, Jiawei Huang, Huilong Chen, Caihou Feng, Yujie Xie, Haiquan He, Ying Chen, Cui Li, Bomeng Wu, et al.

    Minimally invasive esophagectomy for cancer surgery remains associated with significant morbidity and surgical complications across the globe. Non-intubation video-assisted thoracic surgery (NIVATS) has been successfully employed in lung resection in recent years, but there are few reported cases with regard to the safety and feasibility of this approach in radical esophagectomy for patients with esophageal cancers. We present 4 consecutive cases with esophageal squamous cell carcinoma (ESCC) who received minimally invasive McKeown’s esophagectomy under non-intubation general anesthesia from November 2022 to April 2023. All these patients were aged from 55 to 75 years old and were pathologically diagnosed with ESCC. All procedures of McKeown’s esophagectomy in these patients were completed with non-invasive ventilation by laryngeal mask-assisted anesthesia. Operation duration ranged from 185 to 395 minutes and the estimated blood loss ranged from 25 to 60 ml in these 4 cases. No severe hypoxia was observed and transient hypercapnia was resolved intraoperatively. None of them was converted to endotracheal intubation with mechanical ventilation or to thoracotomy. The number of retrieved lymph nodes in mediastinum were 21-27 and all patients received R0 surgery with pathological stage as T1bN0M0 to T3N2M0. There was no serious complication (Clavien-Dindo grade III-IV) observed perioperatively and they were all discharged 11-14 days after the surgery with resumption of oral feeding. They are all alive without tumor recurrence at the date of data collection. The safety and efficacy of minimally invasive esophagectomy with non-invasive ventilation by laryngeal mask-assisted anesthesia for patients with ESCC are warranted for explored in a larger cohort study.